Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ArQule expects $48.7M from offering as it advances c-MET inhibitor tivantinib

This article was originally published in Scrip

Executive Summary

The oncology biotech company ArQule has priced a public offering, and has also increased the offering, from a reported 6 million shares to 7.15 million shares. Shares are now priced at $7.30 each, a 2.1% discount to the share price at the close of 10 April. Net proceeds are expected to be about $48.7 million.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC016951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel